medigraphic.com
Instituto Nacional de Salud Pública

2003, Number S3

<< Back Next >>

salud publica mex 2003; 45 (S3)

Screening for cervical cancer:New alternatives and research

Lörincz AT

Language: English
References: 53
Page: 376-387
PDF size: 122.28 Kb.


ABSTRACT

Evidence for the clinical utility of human papillomavirus (HPV) DNA testing has increased over the years and has now become very convincing. Some specific uses of HPV detection are a) triage of women with cytological determinations of atypical squamous cells of undetermined significance (ASC-US) and related management strategies, b) as a marker for test of cure post-treatment, and c) most importantly, as an adjunct to cytology in routine cervical disease screening programs. There are many studies that support each of these applications and include 8 studies on ASC-US triage, 10 on test of cure and 13 on adjunctive or stand-alone HPV screening. The most notable investigation of ASC-US triage was ALTS, a randomized controlled trial of 3 488 women. With respect to routine HPV screening the combined studies included 77 000 women, providing as a histological endpoint more than 1 000 cases of high-grade cervical intraepithelial neoplasia (CIN) or cancer. Testing methods were either the Hybrid Capture 2 (HC2) test or the polymerase chain reaction (PCR) test. HPV testing of women with ASC-US cytology had on average a higher sensitivity (90%) and specificity (70%) than repeating the cytological test (sensitivity 75%, specificity 60%) and was also more sensitive than colposcopy for follow-up. As an adjunct to the Papanicolaou (Pap) cytology test in routine screening, HPV DNA testing was a more sensitive indicator for prevalent highgrade CIN than either conventional or liquid cytology. A combination of HPV DNA and Papanicolaou testing had almost 100% sensitivity and negative predictive value. The specificity of the combined tests was slightly lower than the specificity of the Papanicolaou test. One “double-negative” HPV DNA and Papanicolaou test indicated a higher prognostic assurance against risk of future CIN 3 than three subsequent negative conventional Papanicolaou tests and may safely allow threeyear or longer screening intervals for such low- risk women. It appears that HPV DNA testing is on the way to becoming a common testing strategy in cervical cancer prevention programs. Research continues into approaches for improving the performance and cost-effectiveness of HPV detection methods. Hybrid Capture 3 will offer improved HPV typing capabilities and the Rapid Capture machine allows for robotassisted HPV DNA testing, permitting greater test throughput.PCR test improvements are expected to contribute to the growth of flexible accurate and cost-effective HPV DNA tests. It is likely that improved diagnostic technology along with HPV genotyping and quantitation may provide more value in future. A particularly promising approach is to combine HPV DNA testing with expression levels of other markers such as proliferative or cell cycle regulatory proteins to subdivide HPVpositive women into those who are at greater risk of cancer and those who can be safely followed by screening at longer intervals.


REFERENCES

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001 Oct;94(2):153-156.

  2. Lazcano-Ponce EC, Rascón-Pacheco RA, Lozano-Ascencio R, Velasco-Mondragón HE. Mortality from cervical carcinoma in Mexico: Impact of screening, 1980-1990. Acta Cytol 1996;40(3):506-512.

  3. Papanicolaou GN, Traut HF. The diagnostic value of vaginal smears in carcinoma of the uterus. Am J Obstet Gynecol 1941 Aug;42(2):193-206.

  4. Nanda K, McCrory DC, Myers ER, Bastian LA, Hasselblad V, Hickey JD et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: A systematic review. Ann Intern Med 2000 May;132(10):810-819.

  5. Bastian L, Datta S, Hasselblad V, Hickey J, Myers E, Nanda K. Evaluation of Cervical Cytology. Rockville, MD: Agency for Health Care Policy and Research; Feb 1999. Report no 5. Available from: http://hstat.nlm.nih.gov/. Accessed July 22, 2003.

  6. Fahey MT, Irwig L, Macaskill P. Meta-analysis of Pap test accuracy. Am J Epidemiol 1995 Apr;141(7):680-689.

  7. Bosch FX, Lörincz A, Muńoz N, Meijer CJLM, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002 Apr;55(4):244-65.

  8. Lörincz AT, Reid R, Jenson AB, Greenberg MD, Lancaster W, Kurman RJ. Human papillomavirus infection of the cervix: Relative risk associations of 15 common anogenital types. Obstet Gynecol 1992 Mar;79(3):328-337.

  9. Bosch FX, Manos MM, Muńoz N, Sherman M, Jansen AM, Peto J et al. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective. J Natl Cancer Inst 1995 Jun;87(11):796-802.

  10. Walboomers JMM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999 Jul;189(1):12-19.

  11. Herrero R, Hildesheim A, Bratti C, Sherman ME, Hutchinson M, Morales J et al. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst 2000 Mar;92(6):464-474.

  12. Thomas DJ. Sexually transmitted viral infections: Epidemiology and treatment. JOGNN 2001;30(3):316-323.

  13. Lörincz A, Anthony J. Advances in HPV detection by Hybrid Capture®. Pap Report 2001;12(6):145-154.

  14. Belinson J, Qiao YL, Pretorius R, Zhang WH, Elson P, Li L et al. Shanxi Province cervical cancer screening study: A cross-sectional comparative trial of multiple techniques to detect cervical neoplasia. Gynecol Oncol 2001 Nov;83(2):439-444.

  15. Solomon D, Schiffman M, Tarone B, for the ALTS Group. Comparison of three management strategies for patients with Atypical Squamous Cells of Undetermined Significance (ASCUS): Baseline results from a randomized trial. J Natl Cancer Inst 2001 Feb;93(4):293-299.

  16. Kjaer SK, van den Brule AJC, Paull G, Svare EI, Sherman ME, Thomsen BL et al. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: Population based prospective follow up study. Br Med J 2002 Sep;325(7364):572-578.

  17. Hall S, Lörincz A, Shah F, Sherman ME, Abbas F, Paull G et al. Human papillomavirus DNA detection in cervical specimens by Hybrid Capture: Correlation with cytologic and histologic diagnoses of squamous intraepithelial lesions of the cervix. Gynecol Oncol 1996;62:353-359.

  18. Sherman ME, Lörincz AT, Scott DR, Wacholder S, Castle PE, Glass AG et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: A 10-year cohort analysis. J Natl Cancer Inst 2003 Jan;95(1):46-52.

  19. The ASCUS-LSIL Triage Study (ALTS) Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 2003 Jun;188(6):1383-1392.

  20. Sherman ME, Schiffman M, Cox JT. Effects of age and human papilloma viral load on colposcopy triage: Data from the randomized Atypical Squamous Cells of Undetermined Significance/Low-grade Squamous Intraepithelial Lesion Triage Study (ALTS). J Natl Cancer Inst 2002 Jan;94(2):102-107.

  21. Manos MM, Kinney WK, Hurley LB, Sherman ME, Shieh-Ngai J, Kurman RJ et al. Identifying women with cervical neoplasia: Using human papillomavirus DNA testing for equivocal Papanicolaou results. JAMA 1999 May;281(17):1605-1610.

  22. Lonky NM, Félix JC, Naidu YM, Wolde-Tsadik G. Triage of atypical squamous cells of undetermined significance with Hybrid Capture II: Colposcopy and histologic human papillomavirus correlation. Obstet Gynecol 2003 Mar;101(3):481-489.

  23. Paraskevaidis E, Koliopoulos G, Alamanos Y, Malamou-Mitsi V, Lolis ED, Kitchener HC. Human papillomavirus testing and the outcome of treatment for cervical intraepithelial neoplasia. Obstet Gynecol 2001 Nov;98(5 pt 1):833-836.

  24. Chua KL, Hjerpe A. Human papillomavirus analysis as a prognostic marker following conization of the cervix uteri. Gynecol Oncol 1997;66:108-113.

  25. Wright TC, Jr, Denny L, Kuhn L, Pollack A, Lörincz A. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer. JAMA 2000 Jan;283(1):81-86.

  26. Kulasingam SL, Hughes JP, Kiviat NB, Mao C, Weiss NS, Kuypers JM et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: Comparison of sensitivity, specificity, and frequency of referral. JAMA 2002 Oct;288(14):1749-1757.

  27. Cuzick J, Beverley E, Ho L, Terry G, Sapper H, Mielzynska I et al. HPV testing in primary screening of older women. Br J Cancer 1999;81(3):554-558.

  28. Clavel C, Masure M, Bory JP, Putaud I, Mangeonjean C, Lorenzato F et al. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer 2001;89(12):1616-1623.

  29. Ratnam S, Franco EL, Ferenczy A. Human papillomavirus testing for primary screening of cervical cancer precursors. Cancer Epidemiol Biomarkers Prev 2000 Sep;9(9):945-951.

  30. Salmerón J, Lazcano-Ponce E, Lörincz A, Hernández M, Hernández P, Leyva A et al. Comparison of HPV-based assays with Papanicolaou smears for cervical cancer screening in Morelos State, Mexico. Cancer Causes Control 2003 Aug;14(6):505-512.

  31. Petry KU, Menton S, Menton M, van Loenen-Frosch F, de Carvalho Gomes H, Holz B et al. Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8468 patients. Br J Cancer 2003 May;88(10):1570-1577.

  32. Schiffman M, Herrero R, Hildesheim A, Sherman ME, Bratti M, Wacholder S et al. HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. JAMA 2000 Jan;283(1):87-93.

  33. Schneider A, Hoyer H, Lotz B, Leistritz S, Kuhne-Heid R, Nindl I et al. Screening for high-grade cervical intra-epithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy. Int J Cancer 2000 Nov;89(6):529-534.

  34. Schiffman MH, Bauer HM, Hoover RN, Glass AG, Cadell DM, Rush BB et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 1993 Jun;85(12):958-964.

  35. Liaw KL, Glass AG, Manos MM, Greer CE, Scott DR, Sherman M et al. Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions. J Natl Cancer Inst 1999 Jun;91(11):954-960.

  36. Castle PE, Wacholder S, Lörincz AT, Scott DR, Sherman ME, Glass AG et al. A prospective study of high-grade cervical neoplasia risk among human papillomavirus infected women. J Natl Cancer Inst 2002 Sep;94(18):1406-1414.

  37. Lörincz AT, Castle PE, Sherman ME, Scott DR, Glass AG, Wacholder S et al. Viral load of human papillomavirus and risk of CIN3 or cervical cancer. Lancet 2002 Jul;360(9328):228-229.

  38. Bory JP, Cucherousset J, Lorenzato M, Gabriel R, Quereux C, Birembaut P et al. Recurrent human papillomavirus infection detected with the hybrid capture II assay selects women with normal cervical smears at risk for developing high grade cervical lesions: a longitudinal study of 3 091 women. Int J Cancer 2002 Dec;102(5):519-525.

  39. Lörincz A, Anthony J. Hybrid Capture®: A system for nucleic acid detection by signal amplification technology. In: Van Dyke K, Van Dyke C, Woodfork K, Ed. Luminescence biotechnology: Instruments and applications. Boca Raton,FL: CRC Press; 2002:149-158.

  40. von Knebel Doeberitz M. New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections. Eur J Cancer 2002 Nov;38(17):2229-2242.

  41. Lin CT, Tseng CJ, Lai CH, Hsueh S, Huang HJ, Law KS. High-risk HPV DNA detection by Hybrid Capture II: An adjunctive test for mildly abnormal cytologic smears in women >50 years of age. J Reprod Med 2000 Apr;45(4):345-350.

  42. Shlay JC, Dunn T, Byers T, Baron AE, Douglas JM, Jr. Prediction of cervical intraepithelial neoplasia 2-3 using risk assessment and human papillomavirus testing in women with atypia on Papanicolaou smears. Obstet Gynecol 2000 Sep;96(3):410-416.

  43. Zielinski GD, Snijders PJF, Rozendaal L, Voorhorst FJ, van der Linden HC, Runsink AP et al. HPV presence precedes abnormal cytology in women developing cervical cancer and signals false negative smears. Br J Cancer 2001 Aug;85(3):398-404.

  44. Morin C, Bairati I, Bouchard C, Fortier M, Roy M, Moore L et al. Managing atypical squamous cells of undetermined significance in Papanicolaou smears. J Reprod Med 2001 Sep;46(9):799-805.

  45. Pretorius RG, Peterson P, Novak S, Azizi F, Sadeghi M, Lörincz AT. Comparison of two signal-amplification DNA tests for high-risk HPV as an aid to colposcopy. J Reprod Med 2002 Apr;47(4):290-298.

  46. Elfgren K, Bistoletti P, Dillner L, Walboomers JMM, Meijer CJLM, Dillner J. Conization for cervical intraepithelial neoplasia is followed by disappearance of human papillomavirus deoxyribonucleic acid and a decline in serum and cervical mucus antibodies against human papillomavirus antigens. Am J Obstet Gynecol 1996 Mar;174(3):937-942.

  47. Bollen LJM, Tjong-A-Hung SP, van der Velden J, Mol BW, Boer K, ten Kate FWJ, Bleker OP, ter Schegget J. Clearance of cervical human papillomavirus infection by treatment for cervical dysplasia. Sex Transm Dis 1997 Sep;24(8):456-460.

  48. Nagai Y, Maehama T, Asato T, Kanazawa K. Persistence of human papillomavirus infection after therapeutic conization for CIN 3: is it an alarm for disease recurrence? Gynecol Oncol 2000;79(2):294-299.

  49. Kjellberg L, Wadell G, Bergman F, Isaksson M, Angstrom T, Dillner J. Regular disappearance of the human papillomavirus genome after conization of cervical dysplasia by carbon dioxide laser. Am J Obstet Gynecol 2000 Nov;183(5):1238-1242.

  50. Lin CT, Tseng CJ, Lai CH, Hsueh S, Huang KG, Huang HJ et al. Value of human papillomavirus deoxyribonucleic acid testing after conization in the prediction of residual disease in the subsequent hysterectomy specimen. Am J Obstet Gynecol 2001 Apr;184(5):940-945.

  51. Jain S, Tseng CJ, Horng SG, Soong YK, Pao CC. Negative predictive value of human papillomavirus test following conization of the cervix uteri. Gynecol Oncol 2001 Jul;82(1):177-180.

  52. Elfgren K, Jacobs M, Walboomers JMM, Meijer CJLM, Dillner J. Rate of human papillomavirus clearance after treatment of cervical intraepithelial neoplasia. Obstet Gynecol 2002 Nov;100(5 pt 1):965-971.

  53. Bodner K, Bodner-Adler B, Wierrani F, Kimberger O, Denk C, Grunberger W. Is therapeutic conization sufficient to eliminate a highrisk HPV infection of the uterine cervix? A clinicopathological analysis. Anticancer Res 2002;22(6B):3733-3736.




2020     |     www.medigraphic.com